Siglecs as sensors of self in innate and adaptive immune responses

Annals of the New York Academy of Sciences

Volumn 1253, Issue 1, 2012, Pages 37-48

  Paulson, James C ^a   MacAuley, Matthew S ^a   Kawasaki, Norihito ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

B cell; Macrophage; Sialic acid; Siglec; Toll like receptors

Indexed keywords

BINDING PROTEIN; CD22 ANTIGEN; SIALIC ACID; SIGLEC; SIGLEC 11; SIGLEC 14; SIGLEC 5; SIGLEC 9; SIGLEC E; SIGLEC G; SIGLEC H; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INNATE IMMUNITY; NONHUMAN; PROTEIN FUNCTION; REVIEW;

MAMMALIA;

EID: 84860241831     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06362.x     Document Type: Review

References (134)

1. Cao, H. & P.R. Crocker. 2011. Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation? Immunology 132: 18-26.
2. Crocker, P.R., J.C. Paulson & A. Varki. 2007. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7: 255-266.
3. Crocker, P.R. & P. Redelinghuys. 2008. Siglecs as positive and negative regulators of the immune system. Biochem. Soc. Trans. 36: 1467-1471.
4. Liu, Y., G.Y. Chen & P. Zheng. 2011. Sialoside-based pattern recognitions discriminating infections from tissue injuries. Curr. Opin. Immunol. 23: 41-45.
5. Nitschke, L. 2009. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol. Rev. 230: 128-143.
6. Pillai, S., A. Cariappa & S.P. Pirnie. 2009. Esterases and autoimmunity: the sialic acid acetylesterase pathway and the regulation of peripheral B cell tolerance. Trends Immunol. 30: 488-493.
7. von Gunten, S. & B.S. Bochner. 2008. Basic and clinical immunology of Siglecs. Ann. N.Y. Acad. Sci. 1143: 61-82.
8. Walker, J.A. & K.G. Smith. 2008. CD22: an inhibitory enigma. Immunology 123: 314-325.
9. Varki, A. 2009. Natural ligands for CD33-related Siglecs? Glycobiology 19: 810-812.
10. Lajaunias, F., J.M. Dayer & C. Chizzolini. 2005. Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. Eur. J. Immunol. 35: 243-251.
11. Avril, T. et al. 2006. Sialic acid-binding immunoglobulin-like lectin 7 mediates selective recognition of sialylated glycans expressed on Campylobacter jejuni lipooligosaccharides. Infect. Immun. 74: 4133-4141.
12. Brinkman-Van der Linden, E.C., et al. 2003. CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice. Mol. Cell Biol. 23: 4199-4206.
13. Carlin, A.F. et al. 2009. Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood 113: 3333-3336.
14. Erdmann, H. et al. 2009. Sialylated ligands on pathogenic Trypanosoma cruzi interact with Siglec-E (sialic acid-binding Ig-like lectin-E). Cell Microbiol. 11: 1600-1611.
15. Khatua, B. et al. 2010. Sialic acids acquired by Pseudomonas aeruginosa are involved in reduced complement deposition and siglec mediated host-cell recognition. FEBS Lett. 584: 555-561.
16. Sinclair, N.R. 1999. Why so many coinhibitory receptors? Scand. J. Immunol. 50: 10-13.
17. Huck, S. et al. 2001. Expression of B cell receptor-associated signaling molecules in human lupus. Autoimmunity 33: 213-224.
18. Lanoue, A. et al. 2002. Interaction of CD22 with alpha2, 6-linked sialoglycoconjugates: innate recognition of self to dampen B cell autoreactivity? Eur. J. Immunol. 32: 348-355.
19. Pritchard, N.R. & K.G. Smith. 2003. B cell inhibitory receptors and autoimmunity. Immunology 108: 263-273.
20. Youinou, P. & Y. Renaudineau. 2004. The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases. Thromb. Res. 114: 363-369.
21. Ferry, H. et al. 2005. Analysis of Lyn/CD22 double-deficient B cells in vivo demonstrates Lyn- and CD22-independent pathways affecting BCR regulation and B cell survival. Eur. J. Immunol. 35: 3655-3663.
22. Youinou, P. et al. 2006. B lymphocytes on the front line of autoimmunity. Autoimmun. Rev. 5: 215-221.
23. Duong, B.H. et al. 2010. Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo. J. Exp. Med. 207: 173-187.
24. O'Keefe, T.L. et al. 1996. Hyperresponsive B cells in CD22-deficient mice. Science 274: 798-801.
25. Jellusova, J. et al. 2010. Siglec-G regulates B1 cell survival and selection. J. Immunol. 185: 3277-3284.
26. Jellusova, J. et al. 2010. CD22 x Siglec-G double-deficient mice have massively increased B1 cell numbers and develop systemic autoimmunity. J. Immunol. 184: 3618-3627.
27. Chen, G.Y. et al. 2011. Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. Nat. Biotechnol. 29: 428-435.
28. Chen, G.Y. et al. 2009. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 323: 1722-1725.
29. Liu, Y., G.Y. Chen & P. Zheng. 2009. CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns. Trends. Immunol. 30: 557-561.
30. Jones, C., M. Virji & P.R. Crocker. 2003. Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake. Mol. Microbiol. 49: 1213-1225.
31. Vanderheijden, N. et al. 2003. Involvement of sialoadhesin in entry of porcine reproductive and respiratory syndrome virus into porcine alveolar macrophages. J. Virol. 77: 8207-8215.
32. Bax, M. et al. 2011. Campylobacter jejuni lipooligosaccharides modulate dendritic cell-mediated T cell polarization in a sialic acid linkage-dependent manner. Infect. Immun. 79: 2681-2689.
33. O'Reilly, M.K. & J.C. Paulson. 2009. Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol. Sci. 30: 240-248.
34. von Gunten, S. & H.U. Simon. 2008. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg). Autoimmun. Rev. 7: 453-456.
35. Razi, N. & A. Varki. 1998. Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes. Proc. Natl. Acad. Sci. USA 95: 7469-7474.
36. Razi, N. & A. Varki. 1999. Cryptic sialic acid binding lectins on human blood leukocytes can be unmasked by sialidase treatment or cellular activation. Glycobiology 9: 1225-1234.
37. Nakamura, K. et al. 2002. Lymph node macrophages, but not spleen macrophages, express high levels of unmasked sialoadhesin: implication for the adhesive properties of macrophages in vivo. Glycobiology 12: 209-216.
38. Brinkman-Van der Linden, E.C. & A. Varki. 2003. Probing for masked and unmasked siglecs on cell surfaces. Methods Enzymol. 363: 113-120.
39. Zhang, M. & A. Varki. 2004. Cell surface sialic acids do not affect primary CD22 interactions with CD45 and surface IgM nor the rate of constitutive CD22 endocytosis. Glycobiology 14: 939-949.
40. Attrill, H. et al. 2006. The structure of siglec-7 in complex with sialosides: leads for rational structure-based inhibitor design. Biochem. J. 397: 271-278.
41. Avril, T. et al. 2006. Probing the cis interactions of the inhibitory receptor Siglec-7 with alpha2, 8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of alpha2, 8-sialyltransferase gene expression. J. Leukoc. Biol. 80: 787-796.
42. Hashimoto, Y. et al. 1998. A streptavidin-based neoglycoprotein carrying more than 140 GT1b oligosaccharides: quantitative estimation of the binding specificity of murine sialoadhesin expressed on CHO cells. J. Biochem. 123: 468-478.
43. Freeman, S.D. et al. 1995. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 85: 2005-2012.
44. Collins, B.E. & J.C. Paulson. 2004. Cell surface biology mediated by low affinity multivalent protein-glycan interactions. Curr. Opin. Chem. Biol. 8: 617-625.
45. Bakker, T.R. et al. 2002. Comparison of CD22 binding to native CD45 and synthetic oligosaccharide. Eur. J. Immunol. 32: 1924-1932.
46. Blixt, O. et al. 2003. Sialoside specificity of the siglec family assessed using novel multivalent probes: identification of potent inhibitors of myelin-associated glycoprotein. J. Biol. Chem. 278: 31007-31019.
47. Powell, L.D. et al. 1995. Characterization of sialyloligosaccharide binding by recombinant soluble and native cell-associated CD22. Evidence for a minimal structural recognition motif and the potential importance of multisite binding. J. Biol. Chem. 270: 7523-7532.
48. Floyd, H., L. Nitschke & P.R. Crocker. 2000. A novel subset of murine B cells that expresses unmasked forms of CD22 is enriched in the bone marrow: implications for B-cell homing to the bone marrow. Immunology 101: 342-347.
49. Ramya, T.N. et al. 2010. In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics. Mol. Cell Proteomics. 9: 1339-1351.
50. Danzer, C.P. et al. 2003. Transitional and marginal zone B cells have a high proportion of unmasked CD22: implications for BCR signaling. Int. Immunol. 15: 1137-1147.
51. Collins, B.E. et al. 2004. Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proc. Natl. Acad. Sci. U S A. 101: 6104-6109.
52. Nicoll, G. et al. 2003. Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms. Eur. J. Immunol. 33: 1642-1648.
53. Crocker, P.R. et al. 1990. Ultrastructural localization of a macrophage-restricted sialic acid binding hemagglutinin, SER, in macrophage-hematopoietic cell clusters. Blood 76: 1131-1138.
54. Collins, B.E. et al. 2006. High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells. J. Immunol. 177: 2994-3003.
55. Tateno, H. et al. 2007. Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity. Mol. Cell. Biol. 27: 5699-5710.
56. Chen, W.C. et al. 2010. In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood 115: 4778-4786.
57. O'Reilly, M.K. et al. 2008. Bifunctional CD22 ligands use multimeric immunoglobulins as protein scaffolds in assembly of immune complexes on B cells. J. Am. Chem. Soc. 130: 7736-7745.
58. Powell, L.D. & A. Varki. 1994. The oligosaccharide binding specificities of CD22 beta, a sialic acid-specific lectin of B cells. J. Biol. Chem. 269: 10628-10636.
59. Kelm, S. et al. 1994. Modifications of cell surface sialic acids modulate cell adhesion mediated by sialoadhesin and CD22. Glycoconj. J. 11: 576-585.
60. Bochner, B.S. et al. 2005. Glycan array screening reveals a candidate ligand for Siglec-8. J. Biol. Chem. 280: 4307-4312.
61. Consortium for Functional Glycomics.
62. Angata, T. et al. 2001. Cloning and characterization of a novel mouse Siglec, mSiglec-F: differential evolution of the mouse and human (CD33) Siglec-3-related gene clusters. J. Biol. Chem. 276: 45128-45136.
63. Angata, T. & A. Varki. 2000. Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways. J. Biol. Chem. 275: 22127-22135.
64. Li, N. et al. 2001. Cloning and characterization of Siglec-10, a novel sialic acid binding member of the Ig superfamily, from human dendritic cells. J. Biol. Chem. 276: 28106-28112.
65. Yu, Z. et al. 2001. mSiglec-E, a novel mouse CD33-related siglec (sialic acid-binding immunoglobulin-like lectin) that recruits Src homology 2 (SH2)-domain-containing protein tyrosine phosphatases SHP-1 and SHP-2. Biochem. J. 353: 483-492.
66. Varki, A. 2010. Colloquium paper: uniquely human evolution of sialic acid genetics and biology. Proc. Natl. Acad. Sci. U S A. 107(Suppl 2): 8939-8946.
67. Brinkman-Van der Linden, E.C., et al. 2000. Loss of N-glycolylneuraminic acid in human evolution. Implications for sialic acid recognition by siglecs. J. Biol. Chem. 275: 8633-8640.
68. Naito, Y. et al. 2007. Germinal center marker GL7 probes activation-dependent repression of N-glycolylneuraminic acid, a sialic acid species involved in the negative modulation of B-cell activation. Mol. Cell Biol. 27: 3008-3022.
69. Blixt, O. et al. 2004. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc. Natl. Acad. Sci. USA 101: 17033-17038.
70. Kimura, N. et al. 2007. Human B-lymphocytes express alpha2-6-sialylated 6-sulfo-N-acetyllactosamine serving as a preferred ligand for CD22/Siglec-2. J. Biol. Chem. 282: 32200-32207.
71. Sjoberg, E.R. et al. 1994. Natural ligands of the B cell adhesion molecule CD22 beta can be masked by 9-O-acetylation of sialic acids. J. Cell Biol. 126: 549-562.
72. Cariappa, A. et al. 2009. B cell antigen receptor signal strength and peripheral B cell development are regulated by a 9-O-acetyl sialic acid esterase. J. Exp. Med. 206: 125-138.
73. Surolia, I. et al. 2010. Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature 466: 243-247.
74. Han, S. et al. 2005. Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking. Nat. Chem. Biol. 1: 93-97.
75. Sgroi, D. et al. 1993. CD22, a B cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin. J. Biol. Chem. 268: 7011-7018.
76. Tanaka, Y. & J.J. Kohler. 2008. Photoactivatable crosslinking sugars for capturing glycoprotein interactions. J. Am. Chem. Soc. 130: 3278-3279.
77. Santos, L. et al. 2008. Dendritic cell-dependent inhibition of B cell proliferation requires CD22. J. Immunol. 180: 4561-4569.
78. Martinez-Pomares, L. et al. 1999. Cell-specific glycoforms of sialoadhesin and CD45 are counter-receptors for the cysteine-rich domain of the mannose receptor. J. Biol. Chem. 274: 35211-35218.
79. Ikehara, Y., S.K. Ikehara & J.C. Paulson. 2004. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. J. Biol. Chem. 279: 43117-43125.
80. Zhang, J.Q. et al. 2000. Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes. J. Biol. Chem. 275: 22121-22126.
81. Nicoll, G. et al. 1999. Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J. Biol. Chem. 274: 34089-34095.
82. Tedder, T.F., J.C. Poe & K.M. Haas. 2005. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv. Immunol. 88: 1-50.
83. Poe, J.C. et al. 2004. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat. Immunol. 5: 1078-1087.
84. Nitschke, L. et al. 1997. CD22 is a negative regulator of B-cell receptor signalling. Curr. Biol. 7: 133-143.
85. Otipoby, K.L. et al. 1996. CD22 regulates thymus-independent responses and the lifespan of B cells. Nature 384: 634-637.
86. Sato, S. et al. 1996. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 5: 551-562.
87. Hoffmann, A. et al. 2007. Siglec-G is a B1 cell-inhibitory receptor that controls expansion and calcium signaling of the B1 cell population. Nat. Immunol. 8: 695-704.
88. O'Keefe, T.L. et al. 1999. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J. Exp. Med. 189: 1307-1313.
89. Mary, C. et al. 2000. Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice. J. Immunol. 165: 2987-2996.
90. Cornall, R.J. et al. 1998. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 8: 497-508.
91. Grewal, P.K. et al. 2006. ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling. Mol. Cell Biol. 26: 4970-4981.
92. Nussenzweig, M.C. et al. 2005. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp.l Med. 201: 703-711.
93. Doody, G.M. et al. 1995. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science 269: 242-244.
94. Otipoby, K.L., K.E. Draves & E.A. Clark. 2001. CD22 regulates B cell receptor-mediated signals via two domains that independently recruit Grb2 and SHP-1. J. Biol. Chem. 276: 44315-44322.
95. Tuscano, J.M. et al. 1996. Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22. Eur. J. Immunol. 26: 1246-1252.
96. Tedder, T.F. et al. 2000. CD22 forms a quaternary complex with SHIP, Grb2, and Shc-a pathway for regulation of B lymphocyte antigen receptor-induced calcium flux. J.Biol. Chem. 275: 17420-17427.
97. Smith, K.G. et al. 1998. Inhibition of the B cell by CD22: a requirement for Lyn. J. Exp. Med. 187: 807-811.
98. Tooze, R.M., G.M. Doody & D.T. Fearon. 1997. Counterregulation by the coreceptors CD19 and CD22 of MAP kinase activation by membrane immunoglobulin. Immunity 7: 59-67.
99. Leprince, C. et al. 1993. CD22 associates with the human surface IgM-B-cell antigen receptor complex. Proc. Natl. Acad. Sci. USA. 90: 3236-3240.
100. Peaker, C.J. & M.S. Neuberger. 1993. Association of CD22 with the B cell antigen receptor. Eur. J. Immunol. 23: 1358-1363.
101. Cyster, J.G. & C.C. Goodnow. 1997. Tuning antigen receptor signaling by CD22: integrating cues from antigens and the microenvironment. Immunity 6: 509-517.
102. Kelm, S. et al. 2002. The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound. J. Exp. Med. 195: 1207-1213.
103. Yu, J. et al. 2007. Synthetic glycan ligand excludes CD22 from antigen receptor-containing lipid rafts. Biochem. Biophys. Res. Commun. 360: 759-764.
104. Collins, B.E. et al. 2006. Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. Nat. Immunol. 7: 199-206.
105. Pierce, S.K. 2002. Lipid rafts and B-cell activation. Nat. Rev. Immunol. 2: 96-105.
106. Kawasaki, N., C. Rademacher & J.C. Paulson. 2011. CD22 regulates adaptive and innate immune responses of B cells. J. Innate. Immun. 3: 411-419.
107. Courtney, A.H. et al. 2009. Sialylated multivalent antigens engage CD22 in trans and inhibit B cell activation. Proc. Natl. Acad. Sci. USA. 106: 2500-2505.
108. von Boehmer, H. & F. Melchers. 2010. Checkpoints in lymphocyte development and autoimmune disease. Nat. Immunol. 11: 14-20.
109. Wardemann, H. & M.C. Nussenzweig. 2007. B-cell self-tolerance in humans. Adv. Immunol. 95: 83-110.
110. Basten, A. & P.A. Silveira. 2010. B-cell tolerance: mechanisms and implications. Curr. Opin. Immunol. 22: 566-574.
111. Osorio, F. & C. Reis e Sousa. 2011. Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity 34: 651-664.
112. Kawai, T. & S. Akira. 2011. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34: 637-650.
113. Severi, E., D.W. Hood & G.H. Thomas. 2007. Sialic acid utilization by bacterial pathogens. Microbiology 153: 2817-2822.
114. Vimr, E. & C. Lichtensteiger. 2002. To sialylate, or not to sialylate: that is the question. Trends Microbiol. 10: 254-257.
115. Avril, T. et al. 2004. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells. J. Immunol. 173: 6841-6849.
116. Falco, M. et al. 1999. Identification and molecular cloning of p75/AIRM1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells. J. Exp. Med. 190: 793-802.
117. Naka, T. et al. 2005. Negative regulation of cytokine and TLR signalings by SOCS and others. Adv. Immunol. 87: 61-122.
118. Dalpke, A.H. et al. 2001. Suppressors of cytokine signaling (SOCS)-1 and SOCS-3 are induced by CpG-DNA and modulate cytokine responses in APCs. J. Immunol. 166: 7082-7089.
119. O'Reilly, M.K., H. Tian & J.C. Paulson. 2011. CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells. J. Immunol. 186: 1554-1563.
120. Blasius, A. et al. 2004. A cell-surface molecule selectively expressed on murine natural interferon-producing cells that blocks secretion of interferon-alpha. Blood 103: 4201-4206.
121. Blasius, A.L. & M. Colonna. 2006. Sampling and signaling in plasmacytoid dendritic cells: the potential roles of Siglec-H. Trends Immunol. 27: 255-260.
122. Zhang, J. et al. 2006. Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood 107: 3600-3608.
123. Wang, Y. & H. Neumann. 2010. Alleviation of neurotoxicity by microglial human Siglec-11. J. Neurosci. 30: 3482-3488.
124. Ando, M. et al. 2008. Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifs. Biochem. Biophys. Res. Commun. 369: 878-883.
125. Yamanaka, M. et al. 2009. Deletion polymorphism of SIGLEC14 and its functional implications. Glycobiology 19: 841-846.
126. Boyd, C.R. et al. 2009. Siglec-E is up-regulated and phosphorylated following lipopolysaccharide stimulation in order to limit TLR-driven cytokine production. J. Immunol. 183: 7703-7709.
127. Bax, M. et al. 2007. Dendritic cell maturation results in pronounced changes in glycan expression affecting recognition by siglecs and galectins. J. Immunol. 179: 8216-8224.
128. Lock, K. et al. 2004. Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells. Immunobiology 209: 199-207.
129. Cieslewicz, M.J. et al. 2005. Structural and genetic diversity of group B streptococcus capsular polysaccharides. Infect. Immun. 73: 3096-3103.
130. Aspinall, G.O. et al. 1994. Lipopolysaccharides from Campylobacter jejuni associated with Guillain-Barre syndrome patients mimic human gangliosides in structure. Infect. Immun. 62: 2122-2125.
131. Tateno, H., P.R. Crocker & J.C. Paulson. 2005. Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6′-sulfo-sialyl Lewis X as a preferred glycan ligand. Glycobiology 15: 1125-1135.
132. Hartnell, A. et al. 2001. Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. Blood 97: 288-296.
133. Brinkman-Van der Linden, E.C. & A. Varki. 2000. New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins. J. Biol. Chem. 275: 8625-8632.
134. Yamaji, T. et al. 2002. A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to alpha 2, 8-disialyl and branched alpha 2, 6-sialyl residues. A comparison with Siglec-9. J. Biol. Chem. 277: 6324-6332.